TIDMVAL
RNS Number : 6317P
ValiRx PLC
18 February 2021
("ValiRx", the "Company" or the "Group")
Director/PDMR Shareholdings
London, UK - ValiRx plc (AIM:VAL), a clinical stage drug
development company, announces that it has received notifications
on 18 February 2021 of the following share purchases by certain
Directors and PDMRs of the Company.
Name Number Purchase Date of Number Number Percentage
of shares price purchase of shares of shares shareholding
purchased held prior held following of issued
to purchase purchase share capital
following
purchase
Kevin Cox
(Director) 22,000 22.25p 17/02/2021 250,333 272,333 0.42%
----------- --------- ----------- ------------- ---------------- ---------------
Gerry Desler
(Director) 22,000 22.75p 18/02/2021 81,668 103,668 0.16%
----------- --------- ----------- ------------- ---------------- ---------------
Martin Lampshire
(Director) 44,000 22.70p 18/02/2021 - 44,000 0.07%
----------- --------- ----------- ------------- ---------------- ---------------
Mark Treharne
(PDMR) 6,095 22.78p 17/02/2021 - 6,095 0.01%
----------- --------- ----------- ------------- ---------------- ---------------
Exercise of Warrants
Furthermore, the Company received notifications on 18 February
2021 for the exercise of warrants over 166,666 new ordinary shares
in the Company at an exercise price of 13p each ("New Ordinary
Shares") by Suzanne Dilly and Kevin Alexander, both Directors of
the Company. Details of the exercise are set out in the table
below.
Name Number of Purchase Number of Number Percentage
warrants price shares held of shares shareholding
exercised prior to held following of issued
purchase exercise share capital
following
exercise
Suzanne Dilly 83,333 13.00p 233,335 316,668 0.49%
----------- --------- ------------- ---------------- ---------------
Kevin Alexander 83,333 13.00p 167,500 250,833 0.39%
----------- --------- ------------- ---------------- ---------------
Total Voting Rights
The Company had previously applied to list these 166,666
ordinary shares as part of the block listing of 9,034,732 ordinary
shares of 0.1 pence each in the Company ("Ordinary Shares") which
was announced on 19 August 2020. They were admitted to trading on
AIM on 24 August 2020.
The total voting rights of the Company comprise 65,049,156
Ordinary Shares which may be used by shareholders (and others with
notification obligations) as the denominator for the calculations
by which they will determine whether they are required to notify
their interest in, or a change to their interest in, the Company
under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014. The Directors of the
Company take responsibility for this announcement.
Ends
For further information please contact:
ValiRx plc Tel: +44 (0) 2476
796496
www.valirx.com
Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray / Jo Turner / Ludovico
Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran 0930
Zucker
Optimum Strategic Communications Tel: +44 (0) 20 8148
Supriya Mathur/ Shabnam Bashir 3040
valirx@optimumcomms.com
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary companies for further
clinical development and commercialisation.
https://www.valirx.com/
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- -----------------------------------------------------------------------------------------------------------
a. Name a) Kevin Cox
b) Gerry Desler
c) Martin Lampshire
d) Mark Treharne
----------------------------------------------------------------
2 Reason for notification
----------------------------------------- ----------------------------------------------------------------
a. Position/Status a) Director
b) Director
c) Director
d) PDMR
----------------------------------------- ----------------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
----------------------------------------- ----------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------------------------
a. Name ValiRx PLC
-----------------------------------------
b. LEI 213800VQKB9SJCQDET40
----------------------------------------- ----------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- -----------------------------------------------------------------------------------------------------------
a. Description Ordinary Shares
of the financial
instrument, ISIN: GB00BLH13C52
type of instrument
Identification
Code
----------------------------------------- ----------------------------------------------------------------
b. Nature of the On market Purchase
transaction
----------------------------------------- ----------------------------------------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
----------------------------------------- --------------------------------------
a) GBP 0.22250 a) 22,000
b) GBP 0.22745 b) 22,000
c) GBP 0.22700 c) 44,000
d) GBP 0.22780 d) 6,095
-------------------------------------- ----------------
d. Aggregated information
- Aggregated 94,095
Volume
- Price GBP0.22610 (weighted average price)
----------------------------------------- ----------------------------------------------------------------
e. Date of the a) 17/02/2021
transaction b) 18/02/2021
c) 18/02/2021
d) 17/02/2021
----------------------------------------- ----------------------------------------------------------------
f. Place of the London, UK
transaction
----------------------------------------- ----------------------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------ ------------------------------------------------------------------------------------------------
a. Name a) Suzanne Dilly
b) Kevin Alexander
---------------------------------------------------------
2 Reason for notification
------------------------------------- ---------------------------------------------------------
a. Position/Status a) Director
b) Director
------------------------------------- ---------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
------------------------------------- ---------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------------
a. Name ValiRx PLC
-------------------------------------
b. LEI 213800VQKB9SJCQDET40
------------------------------------- ---------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------ ------------------------------------------------------------------------------------------------
a. Description of Warrants over new ordinary shares
the financial
instrument, type ISIN: GB00BLH13C52
of instrument
Identification
Code
------------------------------------- ---------------------------------------------------------
b. Nature of the Exercise of warrants over new ordinary shares
transaction at an exercise price of 13p per share
------------------------------------- ---------------------------------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
------------------------------------- -----------------------
a) GBP0.13 83,333
b) GBP0.13 83,333
---------------------------------------------------------------------------- ------------------
d. Aggregated information
- Aggregated 166,666
Volume GBP0.13
- Price
------------------------------------- ---------------------------------------------------------
e. Date of the transaction 18/02/2021
------------------------------------- ---------------------------------------------------------
f. Place of the London, UK
transaction
------------------------------------- ---------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBUGDDLXBDGBI
(END) Dow Jones Newswires
February 18, 2021 10:39 ET (15:39 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024